Public Release: 

Can gene therapy provide a breakthrough in Alzheimer's disease?

Mary Ann Liebert, Inc./Genetic Engineering News

IMAGE

IMAGE: Human Gene Therapy, the Official Journal of the European Society of Gene and Cell Therapy, British Society for Gene and Cell Therapy, French Society of Cell and Gene Therapy, German... view more

Credit: ©Mary Ann Liebert, Inc., publishers

New Rochelle, NY, February 22, 2016--Therapeutic gene transfer to specific brain regions in animal models of Alzheimer's disease has uncovered multiple potential treatment approaches that deserve to be considered as candidates for clinical applications, according to the article "Gene Therapy Strategies for Alzheimer's Disease: An Overview"), published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free to read on the Human Gene Therapy website until March 31, 2016.

The Review is part of a special issue of Human Gene Therapy focusing on advances in gene and cell therapy research in France, led by Guest Editors Nathalie Cartier, MD, Director of Research, INSERM, Paris, and President, European Society of Gene and Cell Therapy (ESGCT), and Pierre Cordelier, PhD, Senior Researcher, INSERM, Toulouse, France, and President, French Society of Cell and Gene Therapy (SFTCG). The special issue will be distributed at the SFTCG meeting, March 9-11, Marseilles, France.

Sandro Alves, Romain Fol, and Nathalie Cartier, INSERM, Université Paris-Sud, Université Paris-Saclay, Orsay, France, present a comprehensive overview of the varied gene therapy approaches in development to target the neuropathological changes associated with Alzheimer's disease. These include strategies intended to act directly on the metabolism of amyloid precursor protein (implicated in amyloid plaque development), to boost neuroprotection, increase levels of autophagy-related proteins (involved in protein turnover and degradation of long-lived proteins), intervene in inflammatory pathways, regulate genes related to lipid metabolism, and target apolipoprotein E (APOE), the major susceptibility gene for Alzheimer's disease.

"Alzheimer's disease is the great challenge of 21st century medicine, looming as an enormous burden to healthcare and society as a whole as the Baby Boom generation ages," says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA. "Gene therapy has the potential to provide the breakthrough that is needed at this critical time."

###

About the Journal

Human Gene Therapy, the Official Journal of the European Society of Gene and Cell Therapy, British Society for Gene and Cell Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies, is an authoritative peer-reviewed journal published monthly in print and online. Led by Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Human Gene Therapy presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Its companion journals, Human Gene Therapy Methods, published bimonthly, focuses on the application of gene therapy to product testing and development, and Human Gene Therapy Clinical Development, published quarterly, features data relevant to the regulatory review and commercial development of cell and gene therapy products. Tables of contents for all three publications and a free sample issue may be viewed on the Human Gene Therapy website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Nucleic Acid Therapeutics, Tissue Engineering, Stem Cells and Development, and Cellular Reprogramming. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.